- Acquired by Arcturus Therapeutics Inc., Nov 2017
- Raised Follow-on PO, Nov 2018
About
Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome. MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome. In 2017, six months after Alcobras clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.
Funding history · 1 round · — total
Headcount over time
Q&A
- What is Alcobra Pharmaceuticals' primary focus?
- Alcobra Pharmaceuticals primarily focuses on the development and commercialization of Metadoxine Extended Release (MDX), a proprietary drug designed to treat cognitive disorders such as attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.
- When was Alcobra Pharmaceuticals founded?
- Alcobra Pharmaceuticals was founded in February 2008.
- What is the current status of Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals is currently inactive, having been acquired by Arcturus Therapeutics Inc. in November 2017.
- What is the employee count for Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals has 1-10 employees.
- What is the total amount of funding raised by Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals raised a total of $25,000,000 USD.
- What is the mechanism of action for Alcobra Pharmaceuticals' drug, MDX?
- MDX is not a stimulant and works through a different mechanism of action compared to other ADHD treatments.
- What clinical trials has Alcobra Pharmaceuticals completed or is currently conducting for MDX?
- Alcobra Pharmaceuticals has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is also conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome.
- What event led to Alcobra Pharmaceuticals' acquisition by Arcturus Therapeutics Inc.?
- In 2017, six months after a clinical trial of its main product for treating attention disorders failed, Alcobra Pharmaceuticals announced its intention to merge with Arcturus Therapeutics Inc. of San Diego, leading to its acquisition.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | www.alcobra-pharma.com |
|---|---|
| linkedin.com/company/5219796 |
Identifiers & details
| Legal name | Alcobra Ltd. |
|---|---|
| Founded | 2008-2 |
| Employees (exact) | 7 |
| Status reason | Acquired (Inactive) by Arcturus Therapeutics Inc. on Nov 2017 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Arcturus Therapeutics Inc. 2017-11
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514098995 |
|---|---|
| Status | מחוסלת מרצון — CLOSED |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-02-07 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2020 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הרכבת 58 תל אביב - יפו |